OPKO Health Appoints James DeMarco As SVP Of Pharmaceutical Sales

OPKO Health, Inc. OPK disclosed that it appointed James DeMarco as its SVP of Pharmaceutical Sales to support the anticipated launch of RAYALDEE. According to the company, DeMarco has more than three decades of commercial pharmaceutical experience with established large companies like Schering Plough, Amgen and Eisai, and emerging companies, apart from a career-long focus on specialty products and nephrology. OPKO said that before joining the company, DeMarco served as a consultant providing commercial leadership services to pharmaceutical, medical device and healthcare services companies. DeMarco was credited for building a number of sales organizations in his career in advance of anticipated product launches in a diverse group of therapeutic areas. The company's Chairman and CEO, Phillip Frost, said that "Jim is uniquely qualified to establish and execute our commercial plans for RAYALDEE in the US. His deep knowledge of the chronic kidney disease market will help bring RAYALDEE to Stage 3 and 4 CKD patients. We look forward to rapidly moving through the final regulatory steps with the FDA and securing an approval." On Monday, shares of the company traded 0.76% down.